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Huntington’s disease (HD) is an autosomal-dominant
neurodegenerative disease caused by the expansion
of polyglutamine repeats in the gene for huntingtin
(Htt). In HD, the corpus striatum selectively degener-
ates despite the uniform expression of mutant hun-
tingtin (mHtt) throughout the brain and body. Striatal
selectivity reflects the binding of the striatal-selective
protein Rhes to mHtt to augment cytotoxicity, but
molecular mechanisms underlying the toxicity have
been elusive. Here, we report that the Golgi protein
acyl-CoA binding domain containing 3 (ACBD3)
mediates mHtt cytotoxicity via a Rhes/mHtt/ACBD3
complex. ACBD3 levels are markedly elevated in
the striatum of HD patients, in a striatal cell line
harboring polyglutamine repeats, and in the brains
of HD mice. Moreover, ACBD3 deletion abolishes
HD neurotoxicity, which is increased by ACBD3 over-
expression. Enhanced levels of ACBD3 elicited by
endoplasmic reticulum, mitochondrial, and Golgi
stresses may account for HD-associated augmenta-
tion of ACBD3 and neurodegeneration.
INTRODUCTION
Huntington’s disease (HD) is an autosomal-dominant neurode-
generative condition associated with mutations in the gene
encoding the protein huntingtin (Htt) that lead to expansion of
glutamine repeats in mutant Htt (mHtt) (The Huntington’s
Disease Collaborative Research Group, 1993). HD patients
display major disruption of motor behavior reflecting massive
and highly selective destruction of the corpus striatum. Surpris-
ingly, Htt and mHtt are expressed uniformly throughout the brain
and the rest of the body despite the striatal selectivity of the
disease. The striatal selectivity of HD may be explained by the
binding of the striatal-selective small G protein Rhes (Ras Homo-
logue Enriched in Striatum) to mHtt, enhancing mHtt-elicited
neurotoxicity (Subramaniam et al., 2009). Reduced Rhes expres-890 Cell Reports 4, 890–897, September 12, 2013 ª2013 The Authorsion is neuroprotective in HD models (Seredenina et al., 2011),
and mice with Rhes deletion are protected from motor distur-
bances in genetic models of HD (Baiamonte et al., 2013) and
from striatal-selective neurotoxicity elicited by 3-nitropropionic
acid (Mealer et al., 2013).
Within the large family of Ras proteins, Rhes most closely
resembles Dexras1, which was first reported as a protein
induced by the glucocorticoid dexamethasone (Kemppainen
and Behrend, 1998). Because of its homology to Dexras1,
Rhes is also designated RASD2. Dexras1 is linked via the carrier
protein CAPON to neuronal nitric oxide synthase (nNOS), with
NO acting as a guanine nucleotide exchange factor for Dexras1
(Fang et al., 2000). The nNOS-Dexras1 complex is also associ-
ated with the Golgi-specific protein acyl-CoA binding domain
containing 3 (ACBD3, previously known as PAP7 or GCP60;
Cheah et al., 2006; Fan et al., 2010). ACBD3, in turn, binds to
Divalent Metal Transporter-1 (DMT1) in a cascade whereby
N-methyl-D-aspartate (NMDA) neurotransmission, acting via
nNOS, CAPON, Dexras1, and ACBD3, regulates neuronal iron
influx (Cheah et al., 2006) and neurotoxicity (Chen et al., 2013).
ACBD3 also binds other components of the Golgi, such as
giantin, Golgin-160, and phosphatidylinositol-4-kinase IIIb
(Sohda et al., 2001; Sbodio et al., 2006; Sasaki et al., 2012;
Greninger et al., 2012). ACBD3 interacts with non-Golgi proteins
such as Translocator Protein of 18 kDa (TSPO, previously known
as Peripheral Benzodiazepine Receptor [PBR]; Li et al., 2001)
and the protein kinase A (PKA) regulatory subunit Ia (Li et al.,
2001). In most of these linkages, ACBD3 appears to act as a
scaffolding protein. The multifunctional role of ACBD3 acting
as a signaling molecule through protein-protein interactions
has been reviewed by Fan et al. (2010).
Because of the close similarity of Rhes to Dexras1, we
wondered whether Rhes also interacts with ACBD3. In the
present study, we demonstrate that ACBD3 participates in a
ternary complex together with Rhes and mHtt. In this complex,
ACBD3 is a major determinant of neurotoxicity, as its over-
expression is cytotoxic and its deletion abolishes Rhes
neurotoxicity. A functional role for ACBD3 in HD is implied by
the strikingly elevated levels of ACBD3 in the brains of patients
with HD as well as in neuronal cell lines with extended glutamine
repeats and in the brains of mice with genetic models of HD.s
(legend on next page)
Cell Reports 4, 890–897, September 12, 2013 ª2013 The Authors 891
ACBD3 levels are upregulated by diverse cellular stresses and
in neuronal cells overexpressing mHtt. Thus, ACBD3 is a
major mediator of HD neurotoxicity with attendant therapeutic
implications.
RESULTS
ACBD3 Physiologically Binds Rhes and mHtt
In human embryonic kidney (HEK) 293 cells, glutathione
S-transferase (GST)-ACBD3 binds overexpressed Rhes (Fig-
ure 1A, left panel), and overexpressed GST-Rhes binds endoge-
nous ACBD3 (Figure 1A, right panel). ACBD3 comprises an
ACBD at the N terminus followed by a nuclear localization signal
(NLS), whereas the C terminus incorporates a Golgi dynamics
domain (GOLD) (Figure 1B). Most of the known ACBD3-interact-
ing proteins, such as giantin, TSPO, PKARIa, and Golgin-160,
bind to the C-terminal GOLD domain (Sohda et al., 2001; Li
et al., 2001; Sbodio et al., 2006). Mapping studies reveal that,
like these other proteins, Rhes binds selectively to the C-terminal
portion of ACBD3 (Figure 1C, left panel).
We also observe substantial binding of overexpressed
wild-type Htt (wtHtt) and mHtt to ACBD3, but unlike Rhes, Htt
and mHtt bind selectively to the N-terminal portion of ACBD3
(Figure 1C, middle and right panels). Coprecipitation studies
indicate a ternary complex of ACBD3 with Rhes and wtHtt or
mHtt (Figures 1D and 1E).
If Htt, Rhes, and ACBD3 are physiologically associated, they
should have similar localizations. Immunofluorescence experi-
ments revealed virtually exclusive localization of ACBD3 to Golgi
(Figure 1F), fitting with earlier studies (Sohda et al., 2001; Sbodio
et al., 2006). Rhes is more widely distributed, but with an intense
focus of immunoreactivity in the Golgi, colocalizing with ACBD3.
Although mHtt occurs throughout the cell, it is most concen-
trated in Golgi together with ACBD3. Rhes, a farnesylated pro-
tein, is also associated with the plasma membrane (Vargiu
et al., 2004). Diverse localizations have been reported for Htt
and mHtt, with nuclear translocation of mHtt fragments during
neurotoxicity (Velier et al., 1998; DiFiglia et al., 1995; Saudou
et al., 1998).
ACBD3 Is Required for Rhes/mHtt Cytotoxicity
In our earlier study (Subramaniam et al., 2009), overexpression of
either Rhes or mHtt alone was not cytotoxic, whereas the com-Figure 1. ACBD3 Binds Rhes and mHtt
(A) HEK 293 cells were transfected with a plasmid encoding myc-Rhes. Aliquot
proteins were separated by SDS-PAGE and immunoblotted using myc antibod
GST-Rhes were harvested and the GST proteins were allowed to bind the g
immunoblotted with ACBD3 antibodies (right panel).
(B) Schematic representation of ACBD3 showing the ACBD, NLS, and GOLD do
(C) Purified GST or GST fused to an N-terminal fragment of ACBD3 (1–175) or a
expressing myc-Htt, myc-mHtt, or myc-Rhes, and bound proteins were detecte
(D) HEK 293 cells were transfected with plasmids encodingmyc-Rhes ormyc-Rhe
purified GST or GST fused to ACBD3. Bound proteins were detected using myc a
transfecting striatal Q111 cells with plasmids encoding GST or GST-Rhes for 16
beads. Bound proteins were detected using ACBD3 or mHtt antibodies.
(E) Schematic representation of ACBD3 binding to Rhes and mHtt.
(F) Q7 and Q111 striatal cells were transfected with plasmid encoding GFP-m
permeabilized, and stained for endogenous ACBD3 and DNA (DAPI).
892 Cell Reports 4, 890–897, September 12, 2013 ª2013 The Authorbination of the two elicited substantial cell death. In HEK 293
cells, we observe modest but significant cell death associated
with Rhes or mHtt overexpression, whereas coexpression of
Rhes and mHtt elicits greater cytotoxicity (Figure 2A). Overex-
pressing ACBD3 by itself leads to cell death comparable to the
combination of ACBD3/mHtt or ACBD3/Rhes. The greatest
cytotoxicity occurs when ACBD3 is coexpressed with Rhes
and mHtt.
A striatal neuronal cell line stably expressing mHtt with 111
glutamines (Q111) models HD cellular dynamics and is routinely
compared with a line of the same cells expressing Htt with seven
glutamines (Q7) (Trettel et al., 2000). In Q7 cells, overexpression
of Rhes, ACBD3, or the combination of Rhes and ACBD3 does
not alter cell survival (Figure 2B). By contrast, in Q111 cells, over-
expression of either Rhes or ACBD3 decreases cell survival,
whereas coexpression produces further cell death (Figure 2C).
To assess whether endogenous ACBD3 is required for Rhes
and/or mHtt cytotoxicity, we depleted ACBD3 by 70% from
HEK 293 cells and Q111 cells using RNAi (Figures 2D and 2E).
In HEK 293 cells, depletion of ACBD3 completely prevents cyto-
toxicity elicited by Rhes/mHtt (Figure 2D). Similarly, depletion of
ACBD3 in Q111 cells abolishes Rhes-associated neurotoxicity
(Figure 2E). As reported earlier (Subramaniam et al., 2009),
mHtt fails to elicit cytotoxicity in these cells in the absence
of Rhes.
ACBD3 Is Upregulated in HD
The abolition of Rhes/mHtt neurotoxicity by depletion of ACBD3
implies a role for ACBD3 in neurotoxicity associated with HD.
ACBD3 protein levels are 50% higher in Q111 cells than in
Q7 cells (Figure 3A). This increase appears to be mediated at
the transcriptional level, as ACBD3 promoter activity, monitored
by luciferase activity, is also substantially greater in Q111 cells
than in Q7 cells (Figure 3B).
Several murine genetic models of HD have been established,
with the R6/2 mice being most widely employed (Li et al.,
2005). In this work, we found that the levels of ACBD3 were
2-fold higher in R6/2 HD mouse brains as compared with wild-
type controls (Figure 3C). Even more impressive is the 2.5-fold
augmentation of ACBD3 levels in striatal samples from patients
with HD (Figure 3D). The substantial increase of ACBD3 levels
in the striatum of HD patients is especially notable because in
HD the striatum profoundly deteriorates with major decreasess of cells were incubated with purified GST or GST fused to ACBD3. Bound
ies (left panel). HEK 293 cells transfected with a plasmid encoding GST or
lutathione sepharose beads. Purified proteins were treated as above and
mains.
C-terminal fragment of ACBD3 (328–528) were incubated with lysates of cells
d using myc antibodies.
s with either myc-Htt (left panel) ormyc-mHtt (middle panel) and incubated with
ntibodies. Binding of Rhes to endogenous ACBD3 and mHtt was detected by
hr (right panel). GST proteins were allowed to bind the glutathione sepharose
Htt(103Q) or GFP-Rhes, and 16 hr after transfection the cells were fixed,
s
Figure 2. ACBD3 Is Required for Rhes/mHtt Toxicity
(A) HEK 293 cells were transfected with plasmids encoding myc-vector (myc), myc-Rhes (R), or myc-mHtt (mH), myc-ACBD3 (A), or in combination R/mH, R/mH/
A, A/mH, or A/R. Cell viability was assessed by MTT assay 48 hr after transfection. *p < 0.005, **p < 0.02, ***p < 0.01.
(B) Q7 striatal cells were transfected with plasmids encoding myc-vector, myc-Rhes, myc-Rhes plus myc-ACBD3, or myc-ACBD3. Cell viability was assessed
as in (A).
(C) Q111 striatal cells were transfected with plasmids encoding myc-vector, myc-Rhes, myc-Rhes plus myc-ACBD3, or myc-ACBD3. Cell viability was assessed
as in (A). *p < 0.02.
(D) HEK 293 cells were cotransfectedwith plasmids encoding human ACBD3 shRNAor control shRNA,myc-Rhes plusmyc-mHtt, ormyc vector. Cell viability was
assessed by MTT assay. *p < 0.01.
(E) Q111 striatal cells were transfected withmouse ACBD3 shRNA or control shRNA. The next day, the cells were transfected again with shRNA together withmyc
or myc-Rhes. *p < 0.002. All of the data in these figures are presented as mean ± SEM.in the levels of many proteins (Seredenina and Luthi-Carter,
2012; Luthi-Carter et al., 2002). Presumably, the increased levels
of ACBD3 in HD enhance the cytotoxicity of striatal Rhes
and mHtt.
ACBD3 Is Induced by Cellular Stress
In HD, damaged mitochondria and endoplasmic reticulum (ER)
are dysfunctional (Roussel et al., 2013; Johri and Beal, 2012).
Thapsigargin, a calcium ATPase pump inhibitor that triggers
ER stress, increases ACBD3 expression in Q7 and Q111Celcells, with the Q111 cells displaying a greater increase in the
levels of ACBD3 (Figure 4A). In the absence of thapsigargin,
ACBD3 levels in Q111 cells are slightly greater than in Q7
cells treated with thapsigargin (Figure 4A). The mitochondrial
complex II inhibitor 3-nitropropionic acid (3NP), which is
frequently used to model HD, also augments ACBD3 levels
(Figure 4B).
The evident role of ACBD3 in HD neurotoxicity suggests that
the Golgi apparatus participates in HD pathophysiology. Golgi
stress has been proposed as a unique form of cell damagel Reports 4, 890–897, September 12, 2013 ª2013 The Authors 893
Figure 3. ACBD3 Is Upregulated in HD
(A) Lysates from Q7 and Q111 striatal cells were
resolved by SDS-PAGE and ACBD3 levels were
quantified. The data are presented as mean ±
SEM. *p < 0.01.
(B) ACBD3 promoter activity was monitored in Q7
and Q111 cells as described in Experimental
Procedures. The data are presented as mean ±
SEM. *p < 0.002.
(C) Striatal lysates from 12-week-old R6/2 mice
were resolved by SDS-PAGE and ACBD3 levels
were quantified (n = 4). The data are presented as
mean ± SEM. *p < 0.02.
(D) Striatal lysates from HD patients were resolved
by SDS-PAGE, and ACBD3 levels were quantified
and presented as mean ± SEM. *p < 0.01.(Oku et al., 2011). The ionophore monensin selectively impacts
the Golgi and is employed as a tool to elicit ‘‘Golgi stress’’
(Oku et al., 2011). During Golgi stress induced by monensin,
ACBD3 is upregulated and appears to translocate to the cytosol
as the Golgi disperses (Oku et al., 2011). In Q7 striatal cells,
monensin increases ACBD3 levels 1.3-fold, almost to the level
of ACBD3 in control Q111 cells (Figure 4C). Upregulation of
ACBD3 by monensin is greater in Q111 cells than in Q7 cells
(Figure 4C).
To examine Golgi stress associated with HD cytotoxicity in the
context of Rhes, we monitored the intracellular localization of
ACBD3 in striatal cell lines overexpressing Rhes (Figure 4D).
These experiments were conducted 48 hr following transfection
with GFP-Rhes, a time when cytotoxicity is elicited. In the
absence of Rhes, Q111 cells display low basal levels of
ACBD3 in the cytoplasm, similar to Q7 cells containing GFP
alone or GFP-Rhes (Figure 4D). By contrast, Rhes overexpres-
sion in Q111 cells elicits a 2.5- to 3-fold increase in ACBD3
cytoplasmic localization, reflecting Golgi stress (Figure 4D) remi-
niscent of ACBD3’s cytosolic translocation elicited by monensin
(Oku et al., 2011). Thus, the cytotoxicity of Rhes/mHtt appears to
be linked to Golgi stress.894 Cell Reports 4, 890–897, September 12, 2013 ª2013 The AuthorsDISCUSSION
In the present study, we demonstrate a
major role for the Golgi protein ACBD3
in HD. ACBD3 levels are markedly
increased in brains of patients with HD,
in brains of genetic HD mice, and in
Q111 striatal cell lines where the increase
appears to involve augmented transcrip-
tion. ACBD3 is physiologically associated
with Rhes and Htt/mHtt in a ternary com-
plex. In this complex, mHtt and Rhes bind
respectively to the N terminus and C ter-
minus of ACBD3, so their binding is not
mutually exclusive, and ACBD3 may be
functioning as a scaffolding protein, as
occurs in other systems. Thus, ACBD3
acts as a scaffold linking the divalent
metal transporter DMT1 with the small Gprotein Dexras1 (Cheah et al., 2006). ACBD3 also displays
scaffolding properties in mitochondria, facilitating the associa-
tion of TSPO, which transports cholesterol into mitochondria
(Midzak et al., 2011), with the regulatory subunit of PKA (Liu
et al., 2006).
Overexpression of ACBD3 enhances Rhes/mHtt cytotoxicity.
More strikingly, depletion of ACBD3 by RNAi abolishes Rhes/
mHtt toxicity, establishing a pathophysiologic role for endoge-
nous ACBD3. Thus, ACBD3 appears to be a critical element of
Rhes/mHtt toxicity, which has been implicated in the pathophys-
iology of HD (Subramaniam et al., 2009; Mealer et al., 2013;
Baiamonte et al., 2013).
ACBD3 is predominantly a Golgi protein. Rhes and mHtt also
display prominent Golgi localizations. These findings suggest a
role for Golgi in mediating cell damage in HD. Nakagomi et al.
(2008) provided evidence for such an association, and reported
that Golgi fragmentation and dispersal precede neuronal cell
death following oxidative/nitrosative insults, excitotoxins, and
ER stress. Moreover, a dominant-negative fragment of a Golgi-
associated protein, GRASP65, blocks Golgi fragmentation and
cell death (Nakagomi et al., 2008). Oku et al. (2011) proposed
that Golgi stress reflects a pathway for cell death, analogous
(legend on next page)
Cell Reports 4, 890–897, September 12, 2013 ª2013 The Authors 895
to ER stress and mitochondrial stress. The Golgi complex pro-
cesses and sorts diverse proteins and lipids that traffic through
the secretory pathway. Velier et al. (1998) characterized roles
for secretory and processing pathways for mHtt that, in part,
involve the Golgi. Post-Golgi trafficking of brain-derived neuro-
trophic factor (BDNF) is damaged by mHtt (del Toro et al., 2006).
The pronounced increase of ACBD3 levels elicited by agents
that impact the Golgi, ER, and mitochondria, coupled with the
marked increase in ACBD3 cytoplasmic staining elicited by
Rhes in Q111 cells, is consistent with a role for ACBD3 in the
neurotoxicity mediated by Rhes/mHtt. The Golgi apparatus
may impact the pathology of other neurodegenerative diseases,
as its fragmentation has been reported in conditions as diverse
as amyotrophic lateral sclerosis, Alzheimer’s disease, Jacob-
Creutzfeldt disease, corticobasal degeneration, and spinocere-
bellar ataxia type 2 (Gonatas et al., 2006).
Our findings may have therapeutic implications. Because
Rhes appears to be responsible for selective striatal damage in
HD, efforts to prevent Rhes-mHtt binding may delay or prevent
the onset of HD. Consistent with this possibility, mice with
genetic deletion of Rhes are resistant to the neuro-
pathology and motor defects elicited by the striatal-selective
toxin 3-nitropropionic acid (Mealer et al., 2013; Baiamonte
et al., 2013). Efforts to decrease the levels of mHtt have been
undertaken as another therapeutic approach in HD (Carroll
et al., 2011). Both Rhes and mHtt bind physiologically to
ACBD3, which appears to function as a scaffold that promotes
their toxicity. Accordingly, agents that block the binding of
ACBD3 to Rhes and/or mHtt may be therapeutic.EXPERIMENTAL PROCEDURES
Cells and Reagents
HEK 293 cells were maintained in normal Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal calf serum, 5 mM glutamine, and
antibiotics. STHdhQ7/Q7 (Q7) and STHdhQ111/Q111 (Q111) were a generous
gift from Marcy MacDonald and were maintained in DMEM containing
400 mg/ml Geneticin (Invitrogen). R6/2 transgenic mice (B6CBA-Tg
[HDexon1]62Gpb/1J) were obtained from Jackson Laboratories. Postmortem
striatal samples from human patients were a gift from Juan Troncoso and Olga
Pletnikova (Division of Neuropathology, Department of Pathology, Johns
Hopkins University). Thapsigargin, 3-nitropropionic acid, and monensin were
obtained from Sigma.Plasmids and Antibodies
Myc (pCMV-myc; Clontech), myc-Rhes, myc-Htt (171-18Q), myc-mHtt(171-
82Q), and pCMV-GST-Rhes were previously described (Subramaniam
et al., 2009). GFP-Rhes was from R.M. Mealer (S.H.S. Laboratory, Johns
Hopkins University). GST-ACBD3(1-175) and GST-ACBD3(328-528) were
previously described (Sbodio et al., 2006). Myc-ACBD3 and full-length GST-
ACBD3 were cloned from GFP-ACBD3 (Sbodio et al., 2006). We obtained
ACBD3 and actin-HRP antibodies from Santa Cruz, myc from Roche, and
mHtt (MAB2166) from Millipore. Secondary antibodies were obtained from GE
Healthcare.Figure 4. ACBD3 Is Induced by Diverse Cell Stressors
(A–C) Q7 and Q111 striatal cells were incubated with 1 mM thapsigargin or DMSO
Cells were harvested and resolved by SDS-PAGE, and ACBD3 levels were quantifi
(D) Q7 and Q111 striatal cells were transfected with plasmids encoding GFP or G
stained for endogenous ACBD3. The Golgi targeting of ACBD3 was analyzed in
ACBD3 localization. *p < 0.001. All of the data in these figures are presented as
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GST constructs expressed in Escherichia coli BL21 (DE3) (Invitrogen), GST-
ACBD3, GST-ACBD3(1-175), and GST-ACBD3(328-528) were purified on
glutathione-sepharose 4B as recommended by the manufacturer (Amersham
Biosciences). Binding assayswere performed as described previously (Sbodio
et al., 2006). Briefly, 10 mg of purified GST or GST fusion proteins bound to
glutathione beads was incubated overnight with lysates of HEK 293 cells
that were previously transfected and harvested in detergent solution
(62.5 mM EDTA, 50 mM Tris-HCl, pH 8, 0.4% deoxycholate, 1% Nonidet
P-40, and protease inhibitors; Sbodio et al., 2006). The bound proteins were
washed three times in detergent solution, eluted in sample buffer, boiled,
resolved by SDS-PAGE, and detected by immunoblotting. For GST-Rhes
binding, assays were performed as described above except that pCMV-
GST-Rhes was transfected in HEK 293 or striatal Q111 cells and purified by
binding it to glutathione beads overnight.
Depletion of ACBD3
ACBD3 was knocked down using small hairpin RNA (shRNA; Santa Cruz).
Briefly HEK 293 cells were cotransfected with plasmids encoding human
ACBD3 shRNA or control shRNA, myc-Rhes and myc-mHtt, or myc alone.
Cell viability was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide (MTT) 72 hr after transfection. Striatal Q111 cells were trans-
fected with plasmids encoding mouse ACBD3 shRNA or control (Santa
Cruz). At 24 hr posttransfection, the cells were transfected again using mouse
ACBD3 shRNA or control, together with myc-Rhes or myc alone. Cell viability
was measured via the MTT assay 48 hr after the second transfection.
Reporter Gene Assays
Q7 and Q111 cells were transfected with the ACBD3 promoter reporter
constructs (Renilla luciferase) and the internal control, TK construct (Cypridina
luciferase; SwitchGear Genomics), and the cells were assayed 72 hr post-
transfection using the dual luciferase kit (SwitchGear Genomics) according
to the manufacturer’s recommendations. The luciferase readings from the
promoter construct were normalized to the values obtained from the TK
construct.
Indirect Immunofluorescence Microscopy
Striatal cells were cultured on coverslips, transfected, and processed as pre-
viously described (Sbodio et al., 2006) 16 hr after transfection for the colocal-
ization experiments and 48 hr after transfection for the ACBD3 Golgi targeting
assay. The localization of ACBD3 (cytoplasmic or Golgi) in the presence or
absence of Rhes was quantified using GFP-tagged Rhes and GFP alone as
a control.
Cell Viability Assay
Cell viability was measured using the MTT assay as recommended by the
manufacturer (Millipore). Briefly, cells were seeded in 24-well or six-well plates
and transfected using Polyfect (QIAGEN) reagent for the HEK 293 cells or
lipofectamine (Invitrogen) for the striatal cells. At 48 hr after transfection,
MTT (0.25 mg/ml) was added to the cells for 45 min. The culture medium
was centrifuged to collect any floating cells. The remaining cells in the well
were lysed in DMSO. The pelleted cells from the culture medium were lysed
in DMSO and added to the original well from which they were taken. Absor-
bance was measured at 570 nm and 630 nm to determine cell viability.
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